Related Experiment Video
Updated: Aug 13, 2026
Optimized Preparation of Whole Murine Tumor-Bearing Lung Tissue for Flow Cytometry and Single-Cell RNA-Sequencing
Published on: May 22, 2026
Epigenetics in lung cancer precision medicine: from bench to bedside-a narrative review
Jianbo Zhou1, Yue Pan1, Guangzhi Ma1
1Department of Thoracic Surgery and Institute of Thoracic Oncology, Frontiers Science Center for Disease-Related Molecular Network, West China Hospital, Sichuan University, Chengdu, China.
Background And Objective:
Lung cancer ranks among the most prevalent malignancies globally. Despite progress in early detection and standard therapies lowering overall mortality, there remains an urgent demand for optimized combinatorial regimens, reliable biomarkers and individualized strategies to advance precision lung cancer care. Epigenetic-targeted agents, represented by DNA methylation and histone lysine deacetylase (HDAC) inhibitors, have exhibited encouraging anti-tumor effects, and the Food and Drug Administration (FDA)-approved EZH2 inhibitor tazemetostat has further validated the translational value of epigenetic therapy across multiple tumors. This narrative review systematically summarizes epigenetic alterations and corresponding targeted inhibitors in lung cancer, and clarifies the clinical prospects of epigenetic tools for diagnostic biomarker development and stratified precision treatment.
Methods:
We searched PubMed and Web of Science Core Collection from database inception to January 31, 2026 with keywords covering lung cancer, DNA methylation, histone modification and epigenetic targeted therapy. Only full-text English original articles and reviews were retained.
Key Content And Findings:
This review systematically characterizes aberrant epigenetic signatures in lung cancer, encompassing DNA methylation, histone methylation, and the recently discovered histone lactylation, while detailing epigenetic biomarkers applicable to diagnosis and targeted therapy. We further summarize subtype-specific research advances of KMT/KDM, HDAC, EZH2 and LSD1 inhibitors in distinct lung cancer subtypes, with core functions including suppressing tumor proliferation, modulating neuroendocrine phenotypic transition, reversing therapeutic resistance, and amplifying anti-tumor immune responses.
Conclusions:
Dysregulated epigenetic modifications serve as core drivers of lung cancer progression, and various epigenetic small-molecule inhibitors possess broad application potential for lung cancer precision treatment. Combined regimens integrating epigenetic agents with immunotherapy or chemotherapy can strengthen anti-tumor responses, yet subtype heterogeneity and unsatisfactory clinical efficacy of some targeted drugs remain major obstacles. The accumulated preclinical and clinical epigenetic evidence summarized herein provides solid theoretical support for developing novel diagnostic biomarkers and individualized stratified therapeutic strategies against lung cancer.
Insights
Epigenetic alterations drive lung cancer. This review details epigenetic inhibitors and biomarkers for precise lung cancer diagnosis and treatment strategies.
Area of Science:
- Oncology
- Epigenetics
- Molecular Biology
Background:
- Lung cancer remains a leading global malignancy with ongoing needs for improved therapies.
- While progress has been made, precision lung cancer care requires optimized combination regimens, reliable biomarkers, and individualized strategies.
- Epigenetic-targeted agents, including DNA methylation and histone deacetylase (HDAC) inhibitors, show promise, with FDA-approved EZH2 inhibitors validating epigenetic therapy's translational value.
Purpose of the Study:
- To systematically review epigenetic alterations and targeted inhibitors in lung cancer.
- To clarify the clinical prospects of epigenetic tools for diagnostic biomarker development.
- To explore stratified precision treatment strategies for lung cancer.
Main Methods:
- A systematic literature search was conducted on PubMed and Web of Science Core Collection.
- Keywords included lung cancer, DNA methylation, histone modification, and epigenetic targeted therapy.
- Only full-text English original articles and reviews were included.
Main Results:
- Aberrant epigenetic signatures in lung cancer, including DNA methylation, histone methylation, and histone lactylation, were characterized.
- Epigenetic biomarkers for diagnosis and targeted therapy were detailed.
- Subtype-specific advances of KMT/KDM, HDAC, EZH2, and LSD1 inhibitors were summarized, highlighting their roles in suppressing proliferation, modulating neuroendocrine transition, reversing resistance, and enhancing anti-tumor immunity.
Conclusions:
- Dysregulated epigenetic modifications are key drivers of lung cancer progression.
- Epigenetic small-molecule inhibitors offer broad potential for precision lung cancer treatment.
- Combined regimens with epigenetic agents, immunotherapy, or chemotherapy can enhance anti-tumor responses, though challenges like subtype heterogeneity persist.
Related Concept Videos
02:50Combination Therapies and Personalized Medicine
The combination of the drug acetazolamide and sulforaphane is a good example of combination therapy to treat cancer. The cells in the interior of a large tumor often die due to the hypoxic and...
01:29Pharmacogenomics: Identification of New Drug Targets